Supplement Table 3. Mean change in body weight from baseline to each post-baseline observation (PP population).

Treatment day, Unit: kg	Tolvaptan (N = 42)			Placebo (N = 39)			Adjust group difference (95% CI)	p value
	N	Mean (SD)	Change (SD)	N	Mean (SD)	Change (SD)
Day 1 (baseline)	42	64.3 (14.5)	--	39	68.0 (15.0)	--	-4.00 (-10.51, 2.52)	0.2254
Day 2	42	63.1 (14.5)	-0.87 (1.20)*	39	67.6 (14.8)	-0.36 (0.88)*	-0.53 (-1.00, -0.06)	0.0292
Day 3	42	62.8 (14.3)	-1.18 (1.54)*	39	67.4 (15.0)	-0.58 (1.07)*	-0.63 (-1.23, -0.04)	0.0379
Day 4	41	63.3 (14.1)	-1.20 (1.94)*	39	67.4 (15.0)	-0.60 (1.29)*	-0.64 (-1.38, -0.11)	0.0918
Post-dosing Day 5	42	62.5 (14.6)	-1.45 (2.19)*	39	67.3 (14.9)	-0.69 (1.31)*	-0.78 (-1.60, 0.04)	0.0614
EOS	42	62.5 (14.6)	-1.45 (2.19)*	39	67.3 (14.9)	-0.69 (1.31)*	-0.78 (-1.60, 0.04)	0.0614

Definition: Post-Dosing Day 5: treatment measurement at post Day 4 dosing examination visit. EOS, end of study, the data represented with the result of post-dosing day 5 analyzed with the last observation carried forward (LOCF) method.

p value: pair t-test for intragroup comparison; Post-Baseline ANCOVA Model: outcome = treatment + baseline level.

* With significant mean change compared to baseline value (intra p value < 0.05).